



## UNITED STATES PATENT AND TRADEMARK OFFICE

10/11  
UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/760,723	01/17/2001	Yasuo Koishihara	53466/295	4861
22428	7590	03/15/2004	EXAMINER	
FOLEY AND LARDNER				EWOLDT, GERALD R
SUITE 500		ART UNIT		PAPER NUMBER
3000 K STREET NW		1644		
WASHINGTON, DC 20007		DATE MAILED: 03/15/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application No.	Applicant(s)
	09/760,723	KOISHIHARA, YASUO
	Examiner	Art Unit
	G. R. Ewoldt, Ph.D.	1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 22 December 2003 and 09 January 2004.

2a) This action is **FINAL**.                    2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 13-24 is/are pending in the application.

4a) Of the above claim(s) 14 is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_\_ is/are allowed.

6) Claim(s) 13 and 15-24 is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All    b) Some \* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_.

4) Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.

5) Notice of Informal Patent Application (PTO-152)

6) Other: \_\_\_\_\_.

**DETAILED ACTION**

1. Claims 13 and 15-24 are being acted upon.
2. In view of Applicant's amendments and responses, filed 12/22/03 and 1/09/04, the previous rejections under the first and second paragraphs of 35 U.S.C. 112 have been withdrawn. In particular, Applicant's argument that the HM1.24 antigen was well known in the art and Applicant's assurances that all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of a patent in U.S. patent applications, were sufficient to overcome the rejections.
3. The Abstract filed 12/22/02 has been found to be acceptable.
4. Applicant is advised that all priority documents were received in the original U.S. filing. It appears that a typographical error occurred on the previous Office Action Summary. The Examiner apologizes for any inconvenience caused to Applicant.
5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.
6. Claims 13 and 15-24 stand rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 5,298,420 (1994) in view of Goto, T., et al. (1994, IDS) for the reasons of record set forth in the paper mailed 9/22/03.

Applicant's arguments, filed 12/22/03, have been fully considered but they are not persuasive. Applicant argues that:

"The cited references do not teach what the Office Action asserts. First, Chang does not teach a method of inhibiting B lymphocyte activation by administering an antibody that binds B cells. Rather, Chang describes a method of killing B lymphocytes via antibody-dependent cellular cytotoxicity (ADCC)."

"Second, Goto does not teach the use of HM1.24 antibodies to treat multiple myeloma. Instead, it teaches only that HM1.24 protein "represents a specific marker of late-stage B-cell

maturity."<sup>2</sup> Although Goto suggests that HM1.24 "potentially serves as a target antigen for immunotherapy of multiple myeloma,"<sup>3</sup> it provides no evidence that HM1.24 actually plays a functional role in multiple myeloma."

Regarding Applicant's first argument, it is the Examiner's position that killing a lymphocyte would encompass inhibiting lymphocyte activation as dead lymphocytes cannot be activated. Regarding Applicant's second argument, given that multiple myeloma is a late-stage B cell neoplasm, the HM1.24 marker need only be present on the neoplastic cell population to be an obvious choice for antibody therapy. Additionally, antibody therapy was well known in the art at the time of the invention and there would have existed a reasonable expectation of success in achieving the inhibition of lymphocyte activation recited in the claims. Accordingly, the rejection is proper and has been maintained.

7. No claim is allowed.

8. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (571) 272-0843. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841.

10. **Please Note:** Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR

or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Additionally, the Technology Center receptionist can be reached at (571) 272-1600.

G.R. Ewoldt, Ph.D.  
Primary Examiner  
Technology Center 1600

*GR Ewoldt*  
3/1/04  
**G.R. EWOLDT, PH.D.**  
**PRIMARY EXAMINER**